Clinical Trial Update: AVID100 in Advanced Epithelial Carcinomas [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of AVID100 for advanced epithelial carcinomas was terminated; results were posted in June 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• AVID100

Snippet

Sponsor: Formation Biologics | Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-06-11